Does N-Acetylcysteine (Parvolex®) prophylaxis reduce the incidence of renal impairment after onpump Coronary Artery Bypass Graft surgery? A prospective randomised controlled trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN71629284

Enrollment

224

Registered

2007-08-21

Start date

2007-08-01

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Renal impairment Urological and Genital Diseases Renal diseases

Interventions

For both groups, there will be no change in routine anaesthetic/surgical or post operative management. The intervention group will be administered 2 g N-Acetylcysteine on the night before surgery (or

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients undergoing elective coronoray artery bypass surgery (onpump) at Wythenshawe Hospital 2. Aged 21 - 80 years

Exclusion criteria

Exclusion criteria: 1. Urgent or emergency cases 2. History of hypersensitivity to N-Acetylcysteine 3. Patients already taking N-Acetylcysteine 4. Patients with renal failure

Design outcomes

Primary

Measure	Time frame
Creatinine clearance and serum creatinine levels on second and fifth post operative day and on discharge.	—

Secondary

Measure	Time frame
Length of Intensive Care Unit (ICU) stay.	—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026